298 patents
Page 8 of 15
Utility
Salts and Solid Forms and Processes of Preparing a PI3K Inhibitor
19 Aug 21
The present disclosure provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3Kδ), as well as a salt form and intermediates related thereto.
Shili Chen, Zhongjiang Jia, Yi Li, Yongchun Pan, Jiacheng Zhou
Filed: 5 Feb 21
Utility
Pyrimidinones As PI3K Inhibitors
19 Aug 21
The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
Filed: 30 Sep 20
Utility
Processes for Preparing Jak Inhibitors and Related Intermediate Compounds
19 Aug 21
Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
Filed: 16 Feb 21
Utility
Bipyrazole Derivatives As Jak Inhibitors
5 Aug 21
Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
Filed: 13 Apr 21
Utility
ANTI-CD73 Antibodies and Uses Thereof
29 Jul 21
Anti-CD73 antibodies are disclosed.
Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane
Filed: 30 Dec 20
Utility
Spiro Compounds As Inhibitors of Kras
29 Jul 21
Le Zhao, Xiaozhao Wang, Wenyu Zhu, Haolin Yin, Liangxing Wu, Wenqing Yao
Filed: 20 Jan 21
Utility
CD73 Inhibitor and A2A/A2B Adenosine Receptor Inhibitor Combination Therapy
29 Jul 21
Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor.
Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
Filed: 30 Dec 20
Utility
Heterocyclic Compounds As Immunomodulators
22 Jul 21
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 24 Aug 20
Utility
Bicyclic Heterocycles As FGFR Inhibitors
15 Jul 21
Jeremy Roach, Artem Shvartsbart, Michael Witten, Wenqing Yao
Filed: 14 Jan 21
Utility
Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
8 Jul 21
The present application provides methods of treating cancer using a combination of an inhibitor of A2A and/or A2B and an inhibitor of PD-1 and/or PD-L1.
Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Luping Lin, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Pramod Unnikrishnan Thekkat, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
Filed: 30 Dec 20
Utility
Tricyclic Heterocycles As Bet Protein Inhibitors
24 Jun 21
Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR., James D. Rodgers
Filed: 11 Dec 20
Utility
Tricyclic Heterocycles As FGFR Inhibitors
10 Jun 21
Matthew S. McCammant, Evan Styduhar, Oleg Vechorkin, Robert Swyka, Wenqing Yao
Filed: 3 Dec 20
Utility
Benzothiazole Compounds and Uses Thereof
10 Jun 21
Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
Filed: 16 Nov 20
Utility
Derivatives of an FGFR Inhibitor
10 Jun 21
The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
Ming Tao, Jason Boer
Filed: 3 Dec 20
Utility
Heteroaryl Amide Compounds As Sting Activators
3 Jun 21
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
Filed: 23 Oct 20
Utility
Salts of a Pim Kinase Inhibitor
27 May 21
The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Jiacheng Zhou, Qun Li
Filed: 13 Jan 21
Utility
Combination Therapy Comprising an ALK2 Inhibitor and a JAK2 Inhibitor
27 May 21
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
Yaoyu CHEN, Matthew C. STUBBS, Ying-Nan Pan CHEN, Michelle PUSEY
Filed: 20 Nov 20
Utility
Pyrrolotriazine Compounds As Tam Inhibitors
20 May 21
Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
Filed: 19 Oct 20
Utility
Imidazopyrimidines and Triazolopyrimidines As A2A / A2B Inhibitors
13 May 21
Xiaozhao Wang, Pei Gan, Heeoon Han, Taisheng Huang, Matthew S. McCammant, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang
Filed: 22 Oct 20
Utility
Salts and Crystalline Forms of a PD-1/PD-L1 Inhibitor
13 May 21
This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Shili Chen, Yi Li, Timothy Martin, Bo Shen, Naijing Su, Jiacheng Zhou, Qun Li
Filed: 10 Nov 20